SUTRO BIOPHARMA INC (STRO) Forecast, Price Target & Analyst Ratings
NASDAQ:STRO • US8693672011
24.45 USD
-0.09 (-0.37%)
At close: Mar 12, 2026
24.45 USD
0 (0%)
After Hours: 3/12/2026, 4:30:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SUTRO BIOPHARMA INC (STRO).
Forecast Snapshot
Consensus Price Target
$33.15
+ 35.58% Upside
Next Earnings Forecast
Release DateMay 6, 2026
PeriodQ4 / 2025
EPS Estimate-$4.43
Revenue Estimate8.508M
ChartMill Buy Consensus
76.25%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$33.15
Upside
+ 35.58%
From current price of $24.45 to mean target of $33.15, Based on 16 analyst forecasts
Low
$8.08
Median
$21.93
High
$105.00
Price Target Revisions
1 Month
-4.01%
3 Months
-15.11%
Price Target Summary
16 Wall Street analysts provided a forecast for the next 12 months for STRO. The average price target is 33.15 USD. This implies a price increase of 35.58% is expected in the next year compared to the current price of 24.45.
The average price target has been revised downward by 15.11% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
76.25%
STRO was analyzed by 16 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about STRO.
In the previous month the buy percentage consensus was at a similar level.
STRO was analyzed by 16 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-20 | Citizens | Upgrade | Market Perform -> Market Outperform |
| 2025-12-22 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-08-12 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-06-16 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2025-05-19 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-04-29 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-03-17 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-03-14 | Citizens Capital Markets | Downgrade | Market Outperform -> Market Perform |
| 2025-03-14 | Wedbush | Downgrade | Outperform -> Neutral |
| 2025-03-14 | B of A Securities | Downgrade | Buy -> Underperform |
| 2024-12-11 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-12-11 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-11 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-10-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-16 | Truist Securities | Maintains | Buy -> Buy |
| 2024-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-05-14 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-05-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-08 | B of A Securities | Initiate | Buy |
| 2024-04-03 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-04-03 | Oppenheimer | Maintains | Outperform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 6, 2026
PeriodQ4 / 2025
EPS Estimate-$4.43
Revenue Estimate8.508M
Revenue Q2Q-42.55%
EPS Q2Q50.21%
Number of Analysts12
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.85%
EPS (1 Month)
0.00%
EPS (3 Months)
-0.56%
Next Earnings Summary
STRO is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -4.43 USD and the consensus revenue estimate is 8.51M USD.
The next earnings revenue estimate has been revised upward by 0.85% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 67.77M 9.52% | 153.731M 126.84% | 62.043M -59.64% | 101.18M 63.08% | 45.092M -55.43% | 51.155M 13.45% | 43.943M -14.10% | 34.268M -22.02% | 46.752M 36.43% | 54.586M 16.76% | 75.963M 39.16% | 87.408M 15.07% | |
| EBITDA YoY % growth | -123.25M -31.56% | -82.462M 33.09% | -231.235M -180.41% | -150.083M 35.10% | -108.671M 27.59% | -81.702M 24.82% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -128.94M -30.88% | -89.278M 30.76% | -238.453M -167.09% | -156.532M 34.36% | -119.511M 23.65% | -97.827M 18.14% | -97.054M 0.79% | -106.047M -9.27% | -90.947M 14.24% | -80.249M 11.76% | -18.319M 77.17% | 6.63M 136.19% | |
| Operating Margin | -190.26% | -58.07% | -384.34% | -154.71% | -265.04% | -191.24% | -220.86% | -309.46% | -194.53% | -147.01% | -24.12% | 7.59% | |
| EPS YoY % growth | -24.40 -6.55% | -17.80 27.05% | -30.20 -69.66% | -22.33 26.06% | -19.78 11.43% | -13.92 29.60% | -0.17 98.75% | -1.73 -900.00% | -1.73 | -1.84 -5.88% | -1.94 -5.56% | -1.94 |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -4.43 50.21% | -9.79 -7.55% | -6.28 -348.44% | -5.56 16.98% | -6.64 -49.86% |
| Revenue Q2Q % growth | 8.508M -42.55% | 10.849M -37.65% | 10.891M -82.91% | 11.749M 21.21% | 10.773M 26.62% |
| EBITDA Q2Q % growth | -31.416M 45.63% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -37.734M 41.95% | -32.752M 31.01% | -32.415M -315.00% | -27.344M 29.71% | -32.702M 13.34% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
15.45%
EPS Next 5 Year
14.20%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-5.27%
Revenue Next 5 Year
-10.65%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
18.50%
EBIT Next 5 Year
N/A
SUTRO BIOPHARMA INC / STRO Forecast FAQ
What is the average price target for SUTRO BIOPHARMA INC (STRO) stock?
16 analysts have analysed STRO and the average price target is 33.15 USD. This implies a price increase of 35.58% is expected in the next year compared to the current price of 24.45.
What is the next earnings date for STRO stock?
SUTRO BIOPHARMA INC (STRO) will report earnings on 2026-05-06.
Can you provide the consensus estimates for SUTRO BIOPHARMA INC next earnings?
The consensus EPS estimate for the next earnings of SUTRO BIOPHARMA INC (STRO) is -4.43 USD and the consensus revenue estimate is 8.51M USD.
What is the consensus rating for STRO stock?
The consensus rating for SUTRO BIOPHARMA INC (STRO) is 76.25 / 100 . This indicates that analysts generally have a positive outlook on the stock.